Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
This finding could lead to very early cancer interventions.
New site-agnostic therapies highlight the importance of genetic testing.
Task force recommends BRCA screening for women at increased cancer risk
To take advantage of these new therapies, people must first learn whether their cancer harbors targetable mutations.
High-tech approach solves ‘real mystery’ in many cancers.
While most gene mutations are harmless, others are not and can spur the formation of cancer.
Dana-Farber researchers have shown that the mutated copy of the gene TP53 sabotages the normal, healthy copy.
First KRAS targeted therapy shows promise for lung and colon cancer
Both have tested positive for the BRCA2 gene mutation.
New study tests ability of natural language processing to search lung cancer patients’ records for treatable mutations.
Q&A: Riki Peters, PhD, MPH, on what this large genome-wide association study means for patients and the public
Tafinlar plus Mekinist shrank tumors in people with biliary tract cancer and adenocarcinoma of the small intestine.
The FDA recently approved Vitrakvi for all cancers with specific gene mutation.
The drug, a PARP inhibitor, blocks proteins that help repair damaged DNA, and so can cause tumor cells that carry a BRCA mutation to die.
As mutations occur, a cell may gain the ability to grow without restraint and invade nearby tissue— to become, in effect, a cancer cell.
Turns out mutations in the TP53 gene are focused on so-called “hot spots” because specific carcinogens target those spots.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.